相似文献
1
Bifaceted functions of histone methyltransferases.
Epigenomics. 2025 Sep;17(13):891-896. doi: 10.1080/17501911.2025.2530925. Epub 2025 Jul 13.
2
Modulatory Effect of Curcumin on Expression of Methyltransferase/Demethylase in Colon Cancer Cells: Impact on wt p53, mutp53 and c-Myc.
Molecules. 2025 Jul 22;30(15):3054. doi: 10.3390/molecules30153054.
3
Arsenic disrupts H3K9me3 and H3K27me3 balance by biasing PRC2.1 and PRC2.2 activity via PALI1 inhibition in carcinogenesis.
Int J Biol Sci. 2025 Jun 9;21(9):4069-4080. doi: 10.7150/ijbs.115605. eCollection 2025.
5
The transcription factor HOXA9 induces expression of the chromatin modifier SMYD3 to drive leukemogenesis.
J Biol Chem. 2025 May 30;301(7):110320. doi: 10.1016/j.jbc.2025.110320.
6
Use of histone methyltransferase inhibitors in cancer treatment: A systematic review.
Eur J Pharmacol. 2023 Apr 5;944:175590. doi: 10.1016/j.ejphar.2023.175590. Epub 2023 Feb 10.
7
The dual functionality of EZH2 in cardiovascular disease: Bridging cancer biology and cardiac pathophysiology through epigenetic regulation, metabolic reprogramming, and novel therapeutic interventions.
Curr Probl Cardiol. 2025 Jun 13;50(9):103104. doi: 10.1016/j.cpcardiol.2025.103104.
8
PQQ Inhibits PRC2 Methyltransferase Activity and Suppresses the Proliferation of B-Cell Lymphoma In Vitro.
Chem Biodivers. 2025 Jul;22(7):e202500198. doi: 10.1002/cbdv.202500198. Epub 2025 Mar 23.
9
Bath: a Bayesian approach to analyze epigenetic transitions reveals a dual role of H3K27me3 in chondrogenesis.
Epigenetics Chromatin. 2025 Jun 27;18(1):38. doi: 10.1186/s13072-025-00594-6.
10
Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.
J Clin Invest. 2024 Oct 15;134(20):e183391. doi: 10.1172/JCI183391.
本文引用的文献
1
SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer.
Sci Rep. 2025 Jan 6;15(1):984. doi: 10.1038/s41598-024-83396-2.
2
Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models.
iScience. 2024 Aug 30;27(9):110854. doi: 10.1016/j.isci.2024.110854. eCollection 2024 Sep 20.
3
EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
Oncogene. 2024 Aug;43(36):2722-2736. doi: 10.1038/s41388-024-03119-9. Epub 2024 Aug 7.
4
The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy.
J Natl Cancer Cent. 2022 Sep 28;2(4):277-290. doi: 10.1016/j.jncc.2022.09.002. eCollection 2022 Dec.
5
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.
Cell Rep. 2023 Jul 25;42(7):112823. doi: 10.1016/j.celrep.2023.112823. Epub 2023 Jul 17.
6
SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.
Cell Death Dis. 2023 Jun 29;14(6):386. doi: 10.1038/s41419-023-05907-9.
7
Chemically induced degradation of epigenetic targets.
Chem Soc Rev. 2023 Jul 3;52(13):4313-4342. doi: 10.1039/d3cs00100h.
8
Use of histone methyltransferase inhibitors in cancer treatment: A systematic review.
Eur J Pharmacol. 2023 Apr 5;944:175590. doi: 10.1016/j.ejphar.2023.175590. Epub 2023 Feb 10.
9
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Oncogene. 2023 Mar;42(13):994-1009. doi: 10.1038/s41388-023-02618-5. Epub 2023 Feb 7.
10
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.
Nat Cell Biol. 2022 Mar;24(3):384-399. doi: 10.1038/s41556-022-00850-x. Epub 2022 Feb 24.
Zotero 插件